Detection of nevirapine in plasma using thin-layer chromatography

被引:13
作者
Dubuisson, JG
King, JR
Stringer, JSA
Turner, ML
Bennetto, C
Acosta, EP
机构
[1] Univ Alabama, Sch Med, Div Clin Pharmacol, Birmingham, AL 35294 USA
[2] Univ Alabama, Sch Med, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
关键词
D O I
10.1097/00126334-200402010-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Nevirapine (NVP) is widely prescribed in resource-poor settings to pregnant women for treatment and prevention of HIV infection. High rates of misreported adherence, however, have compelled clinicians to find alternative methods to ensure systemic drug exposure. This report describes a fast, inexpensive thin-layer chromatography (TLC) method to detect the presence of NVP in human plasma. Methods: Human plasma was spiked with various concentrations of NVP. NVP was subsequently isolated using solid-phase extraction and visualized with TLC. Clinical samples with NVP concentrations predetermined by high-performance liquid chromatography were used to validate the TLC method. Results: NVP was detected at concentrations as low as 60 ng/mL. The lower limit of detection was set at 100 ng/mL due to the clear spot definition at this concentration. The turnaround time for assay results averages several hours, and costs associated with the assay are considerably below standard drug quantitation techniques. Conclusion: TLC provides a rapid, sensitive, and economical tool to qualitatively measure NVP in plasma. This method offers clinicians in resource-poor settings an alternative approach for measuring adherence, particularly in developing-world regions where NVP use is common and there is an immediate need to prevent mother-to-child HIV transmission.
引用
收藏
页码:155 / 157
页数:3
相关论文
共 8 条
[1]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[2]   Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction:: application for the assessment of their transplacental passage at delivery [J].
Marzolini, C ;
Béguin, A ;
Telenti, A ;
Schreyer, A ;
Buclin, T ;
Biollaz, J ;
Decosterd, LA .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02) :127-140
[3]   Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates [J].
Mirochnick, M ;
Fenton, T ;
Gagnier, P ;
Pav, J ;
Gwynne, M ;
Siminski, S ;
Sperling, RS ;
Beckerman, K ;
Jimenez, E ;
Yogev, R ;
Spector, SA ;
Sullivan, JL .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :368-374
[4]   Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: Association with timing of maternal intrapartum nevirapine dose [J].
Mirochnick, M ;
Dorenbaum, A ;
Blanchard, S ;
Cunningham, CK ;
Gelber, RD ;
Mofenson, L ;
Culnane, M ;
Sullivan, JL .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (02) :153-156
[5]  
MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506
[6]   Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine [J].
Stringer, JSA ;
Sinkala, M ;
Chapman, V ;
Acosta, EP ;
Aldrovandi, GM ;
Mudenda, V ;
Stout, JP ;
Goldenberg, RL ;
Kumwenda, R ;
Vermund, SH .
AIDS, 2003, 17 (11) :1659-1665
[7]   Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings [J].
Stringer, JSA ;
Sinkala, M ;
Stout, JP ;
Goldenberg, RL ;
Acosta, EP ;
Chapman, V ;
Kumwenda-Phiri, R ;
Vermund, SH .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (05) :506-513
[8]  
2003, AIDS EPIDEMIC UPDATE